Zaloguj się

Gotowe bibliografie tematyczne / Bisphosphonate / Książki

Książki na temat „Bisphosphonate”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Bisphosphonate.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 11 marca 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych książek naukowych na temat „Bisphosphonate”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Maria, Bijvoet Olav Leonardus, red. Bisphosphonate on bones. Amsterdam: Elsevier, 1995.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Girard, Bruno. Exploring high dose effects of a bisphosphonate (HEBP) on osteogenesis in vitro. [Toronto: Faculty of Dentistry, University of Toronto], 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Catherine, Allison, i Canadian Coordinating Office for Health Technology Assessment., red. An assessment of bisphosphonate drugs to manage pain secondary to bone metastases. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Marx, Robert E. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. Chicago: Quintessence Pub. Co., 2006.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Rebecca, Wong, i Canadian Coordinating Office for Health Technology Assessment., red. Bisphosphonate agents for the management of pain secondary to bone metastases: A systematic review of effectiveness and safety. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. Wyd. 2. Chicago: Quintessence Pub. Co., Inc., 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Ponte, Francesco Saverio De. Bisphosphonates and osteonecrosis of the jaw: A multidisciplinary approach. Milan: Springer, 2012.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Chan, Cary Chung-Keung. Effects of cyclical parathyroid hormone (1-34) fragments and (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate treatment on bone in ovariectomized rats. Ottawa: National Library of Canada, 1994.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Bartl, Reiner, Emmo von Tresckow i Christoph Bartl. Bisphosphonat-Manual. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-31271-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Brunner, Kurt W., Herbert Fleisch i Hans-Jörg Senn, red. Bisphosphonates and Tumor Osteolysis. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83668-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Bartl, Reiner, Bertha Frisch, Emmo von Tresckow i Christoph Bartl. Bisphosphonates in Medical Practice. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-69870-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Thürlimann, Beat. Bisphosphonates in Clinical Oncology. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59845-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Bilezikian, John P., i J. T. Grbic. Bisphosphonates and osteonecrosis of the jaw. Redaktor New York Academy of Sciences. Boston, Mass: Published by Blackwell Pub. on behalf of the New York Academy of Sciences, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Bisphosphonates in clinical oncology: The development of pamidronate. Berlin: Springer, 1999.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

De Ponte, Francesco Saverio, red. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2083-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Fleisch, Herbert. Bisphosphonates in bone disease: From the laboratory to the patient. Bern: H. Fleish, 1993.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Bisphosphonates in bone disease: From the laboratory to the patient. Wyd. 3. New York: Parthenon Pub. Group, 1997.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Bisphosphonates in bone disease: From the laboratory to the patient. Wyd. 2. New York: Parthenon Pub. Group, 1995.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Bisphosphonates in bone disease: From the laboratory to the patient. Wyd. 4. San Diego: Academic Press, 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Suzanne, Morphet, Canadian Coordinating Office for Health Technology Assessment. i Canadian Agency for Drugs and Technologies in Health., red. Bisphosphonates and teriparatide for the prevention of osteoporotic fractures in postmenopausal women. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2006.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Björkroth, J. P. Evaluation of structure-activity relationships in drug design and an application to bisphosphonates. Helsinki: Suomalainen Tiedaekatemia, 1991.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Dirnagl, Lorenz. Unterschiede der Neoangiogenese bei Osteomyelitis, Osteoradionekrose und Bisphosphonat assoziierter Kiefernekrose in perinekrotischem Weichgewebe. [S.l: s.n.], 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Sparidans, Rolf W. Bisphosphonates: A chromatographic approach as a contribution to the clinical evaluation of pamidronate and olpadronate. [Tilburg]: Syntax Publishers, 1997.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

A, Wells George, i Canadian Agency for Drugs and Technologies in Health., red. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: A meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Kruk, Dorothy. The costs and consequences of using bisphosphonates as prophylaxis against the sequelae of bone metastases secondary to breast cancer. Ottawa: National Library of Canada, 2001.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Marx, Robert E. Oral & Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Quintessence Publishing (IL), 2006.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0144.

Pełny tekst źródła

Streszczenie:

Paget's disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

Style APA, Harvard, Vancouver, ISO itp.

28

Ralston, Stuart H. Paget’s disease of bone. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0144_update_001.

Pełny tekst źródła

Streszczenie:

Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

Style APA, Harvard, Vancouver, ISO itp.

29

Ponte, Francesco Saverio De. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Ponte, Francesco Saverio De. Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer Milan, 2016.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Rogers, Mike, Graham Russell i Stuart Ralston. Bisphosphonates. Informa Healthcare, 2002.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Russell, Bertrand. Bisphosphonates. Taylor & Francis Group, 2004.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Thürlimann, Beat. Bisphosphonates in Clinical Oncology. Springer-Verlag, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Senn, Hans-Jörg, Herbert Fleisch i Kurt W. Brunner. Bisphosphonates and Tumor Osteolysis. Springer London, Limited, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Reiner Bartl,Bertha Frisch,Emmo Tresckow. Bisphosphonates in Medical Practice. Springer, 2008.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Bisphosphonates and Tumor Osteolysis. Springer, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Bartl, Reiner, Christoph Bartl i Emmo Tresckow. Bisphosphonat-Manual: Wirkungen - Indikationen - Strategien. Springer London, Limited, 2006.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Bartl, Reiner, Emmo von Tresckow i Christoph Bartl. Bisphosphonat-Manual: Wirkungen - Indikationen - Strategien. Springer, 2005.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne i Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Pełny tekst źródła

Streszczenie:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presentation, staging and role of PET scanning, is described along with current treatment with chemotherapy and limited radiotherapy. Non-Hodgkin lymphoma is another heterogeneous group of diseases, divided into low-grade and high-grade pathology, and varying in their genetics, presentation, and management. Rituximab is a key component of chemotherapy regimens against B-cell lymphoma. Myeloma and other plasma cell dyscrasias are described, and treatment options reviewed. Myeloma remains incurable, but with appropriate management consistent with prolonged good quality life. Treatment includes chemotherapy, bisphosphonate therapy, analgesics and radiotherapy, Throughout this chapter is emphasised the importance of clinical trials in driving the rapid improvements in treatment of these diseases.

Style APA, Harvard, Vancouver, ISO itp.

40

BRUNNER, K. ED. Bisphosphonates & Tumor Osteolysis (Recent Results in Cancer Research). Springer, 1989.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Thürlimann, Beat. Bisphosphonates in Clinical Oncology: The Development of Pamidronate. Springer, 2012.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

(Editor), Kurt W. Brunner, Herbert Fleisch (Editor) i Hans-Jörg Senn (Editor), red. Bisphosphonates and Tumor-Osteolysis (Recent Results in Cancer Research). Springer, 1995.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Bisphosphonates in Medical Practice: Actions - Side Effects - Indications - Strategies. Springer, 2007.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Bartl, Reiner, Bertha Frisch, Christoph Bartl i Emmo Tresckow. Bisphosphonates in Medical Practice: Actions - Side Effects - Indications - Strategies. Springer, 2007.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Rubens, R., red. Bisphosphonates And Metastatic Bone Disease (INTERNATIONAL CONGRESS, SYMPOSIUM/SEMINAR SERIES). Parthenon Publishing Group, 1994.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Fleisch, Herbert. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. Elsevier Science & Technology Books, 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer, 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Bisphosphonates and osteonecrosis of the jaw: proceedings of an international conference. New York Academy of Science, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Otto, Sven, i Sven Ed Otto. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer Berlin / Heidelberg, 2016.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates and Denosumab, and New Agents. Springer, 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!